Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialJ Urol 2022 Jan 01;207(1)61-69, KK Chevli, ND Shore, A Trainer, AB Smith, D Saltzstein, Y Ehrlich, JD Raman, B Friedman, R D'Anna, D Morris, B Hu, M Tyson, A Sankin, M Kates, J Linehan, D Scherr, S Kester, M Verni, K Chamie, L Karsh, A Cinman, A Meads, S Lahiri, M Malinowski, N Gabai, S Raju, M Schoenberg, E Seltzer, WC Huang
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.